BTAI

BTAI is a pre-commercial neuroscience biopharma whose financials describe a company fighting for survival, not one to underwrite on fundamentals. Its own 10-K states there are 'conditions and events that raise substantial doubt regarding our ability to continue as a going concern,' with just $28.8M of cash/restricted cash and no current availability under its funding facilities — management explicitly does 'not believe we have sufficient cash on hand to support current operations and service our debt obligations for at least one year.' The balance sheet is already underwater: stockholders' equity is -$95.5M, liabilities are $140M against $44.9M of assets, and current liabilities exploded +142.5% to $53.9M against $44.7M current assets. Operating cash burn was -$57.6M in FY2025 versus that ~$28M cash pile — the arithmetic alone forces a near-term raise or restructuring.

The 'business' is not carrying it. Revenue is a rounding error — $642K, down 71.7% YoY, actually below FY2023's $1.38M and FY2024's $2.27M — so IGALMI has failed to commercialize meaningfully, and the company admits it now supports it 'with minimal commercial support.' Every year is a large net loss (-$69.9M FY2025), retained deficit is -$720M, and R&D ($30.3M) is being funded out of a shrinking, debt-encumbered treasury. Shareholders are the exit valve: shares outstanding rose 393.5% YoY to 27.1M, and the Ninth Amendment layers on more — a mandatory 50% sweep of capital-raise proceeds to Lenders plus penny warrants for up to 1.35M shares at $0.01. Any equity you buy today is standing in front of both the debt and a structurally guaranteed dilution machine.